Takahashi Nobutaka, Hirashima Yasuyuki, Harashima Shiho, Takekuma Munetaka, Kawaguchi Ryuuji, Yamada Yoshiharu, Ito Ichiro
Department of Gynecology, Shizuoka Cancer Center Hospital, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan.
Arch Gynecol Obstet. 2008 Oct;278(4):365-7. doi: 10.1007/s00404-008-0587-6. Epub 2008 Feb 14.
In the treatment of endometrial carcinoma, young patients desire the preservation of the uterus, and therefore hormonal therapy has been administered.
The patient was a 39-year-old nullipara diagnosed with stage 1a endometrial carcinoma. The patient desired the preservation of the uterus, and oral administration of MPA was prescribed for 18 weeks, which after the cancer tissue disappeared. However, about 1 year and 6 months later, the patient was diagnosed as having recurrent endometrial carcinoma in the left external iliac lymph node.
In the literature, there is no patient with relapse at another site in the absence of endometrial relapse after MPA therapy for stage 1a endometrial carcinoma, as performed in the present patient.
在子宫内膜癌的治疗中，年轻患者希望保留子宫，因此采用了激素治疗。
该患者为39岁未育女性，被诊断为1a期子宫内膜癌。患者希望保留子宫，遂给予口服甲羟孕酮治疗18周，之后癌组织消失。然而，大约1年零6个月后，患者被诊断为左侧髂外淋巴结复发性子宫内膜癌。
在文献中，如本患者对1a期子宫内膜癌进行的甲羟孕酮治疗后，在子宫内膜未复发的情况下，没有患者在其他部位出现复发。
